Latin American consensus on tapering of biological therapy in psoriasis

Simple item page
dc.coverageDOI: 10.1016/j.abd.2025.501134
dc.creatorLondoño-García, Angela María
dc.creatorCastro-Ayarza, Juan Raúl
dc.creatorFranco Franco, Manuel Darío
dc.creatorGonzález Ardila, Cesar Fernando
dc.creatorMagariños, Gabriel
dc.creatorRivas Zaldívar, Enrique Salvador
dc.creatorMartínez, Susan
dc.creatorIbatá, Linda
dc.creatorCastillo, Julieth Carolina
dc.creatorCárdenas Rojas, Paola Jimena
dc.creatorCastro Vargas, Evelyn Giuliana
dc.creatorContreras, Claudia Romina
dc.creatorde la Cruz Fernández, Claudia
dc.creatorChavarriaga Restrepo, Andrés
dc.creatorEcheverria, Cristina Mariela
dc.creatorEsteves de Carvalho, André Vicente
dc.creatorHidalgo Matlock, Benjamín
dc.creatorLoayza, Enrique
dc.creatorMaskin, Matías Rafael
dc.creatorRomiti, Ricardo
dc.creatorValenzuela, Fernando
dc.date2025
dc.date.accessioned2025-11-18T19:56:47Z
dc.date.available2025-11-18T19:56:47Z
dc.description<p>Background: Biologic therapy is an effective psoriasis treatment. However, its long-term use carries the risk of serious adverse effects and high costs for the healthcare system, which is particularly relevant in resource-limited Latin American countries. Therefore, there is scientific interest in exploring the feasibility of tapering therapy in low disease activity or clinical remission. Objective: To provide expert consensus-based recommendations to guide personalized and efficient tapering of biologic agents in adult patients with cutaneous psoriasis. Methods: Following an exhaustive systematic literature review, a consensus was developed using a modified Delphi methodology by a group of Latin American clinical dermatologists and an independent methodological team. The topics covered include treatment goals, tapering objectives and strategies, regimens, monitoring and tapering failure, and implementation considerations in patients with psoriasis treated with biological agents. Results: The expert panel reached a consensus on five general principles and 13 recommendations for tapering biological therapy for psoriasis. These recommendations provide scientific support for dermatologists and healthcare providers regarding criteria for tapering, strategies and regimens, monitoring, failure management, and considerations for implementation. Conclusion: Tapering of biologics appears to be effective and safe in psoriasis patients with low stable activity or clinical remission. This Latin American consensus was developed in recognition of the need for rational and optimal use of biologics, while individualizing cases to apply best clinical practices.</p>eng
dc.identifierhttps://investigadores.uandes.cl/en/publications/0a4b7641-0e9c-467f-ad07-e80297cc3362
dc.identifier.urihttps://repositorio.uandes.cl/handle/uandes/59983
dc.languageeng
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourcevol.100 (2025) date: 2025-07-01 nr.4
dc.subjectBiological therapy
dc.subjectConsensus
dc.subjectDelphi technique
dc.subjectDrug tapering
dc.subjectLatin America
dc.subjectPsoriasis
dc.titleLatin American consensus on tapering of biological therapy in psoriasiseng
dc.typeArticleeng
dc.typeArtículospa
Files
Collections
PURE